A Phase I Study of LOXO-260 in People with Solid Tumors Containing RET Gene Changes

Share

Full Title

A Phase 1 Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors

Purpose

The RET gene plays a role in the growth and survival of normal cells, but a change in the gene may fuel the growth of cancer cells. In this study, researchers are finding the highest dose of the investigational drug LOXO-260 that can be given safely in people with solid tumors that continue to grow despite treatment and contain changes in the RET gene. LOXO-260 blocks the RET protein (which is made by the RET gene), and this blocking action may slow or stop cancer growth. LOXO-260 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an inoperable or metastatic solid tumor that has continued to grow despite treatment and contains either a mutation or a fusion (when parts of two different genes are joined together) in the RET gene.
  • Patients may have previously received another RET inhibitor.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Drilon at 646-608-3758.

Protocol

22-249

Phase

I

Investigator

Co-Investigators

Diseases